Recorded live on Tuesday, September 8, 2020, from 2:00 PM ET to 3:00 PM ET • Hosted jointly by the TCC & TxPharm Communities of Practice
"Effects of mTOR inhibitor–related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients."
(Am J Transplant. 2020 Jun 18. doi: 10.1111/ajt.16155. Online ahead of print.)
In this article:
[The authors] previously described the use of sirolimus (SRL) as primary immunosuppression following heart transplantation (HT). The advantages of this approach include attenuation of cardiac allograft vasculopathy (CAV), improvement in glomerular filtration rate (GFR), and reduced malignancy. However, in some patients SRL may cause significant proteinuria. [The authors] sought to investigate the prognostic value of proteinuria after conversion to SRL. CAV progression and adverse clinical events were studied... [Results] indicate that proteinuria is a marker of baseline renal dysfunction, and that HT recipients who develop proteinuria after conversion to SRL have less attenuation of CAV progression and higher mortality risk.
Richard Daly, MD • Mayo Clinic College of Medicine, Rochester, MN
Sudhir Kushwaha, MD • Mayo Clinic College of Medicine, Rochester, MN
Douglas Jennings, PharmD, FACC, FAHA, FHFSA • Columbia University, New York, NY